Yonghe Medical Group Yönetim

Yönetim kriter kontrolleri 3/4

Yonghe Medical Group CEO'su Yu Zhang, Jul2010 tarihinde atandı, in görev süresi 14.33 yıldır. in toplam yıllık tazminatı CN¥ 1.72M olup, şirket hissesi ve opsiyonları dahil olmak üzere 96% maaş ve 4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 36.29% ine doğrudan sahiptir ve bu hisseler HK$ 136.15M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 3.4 yıldır.

Anahtar bilgiler

Yu Zhang

İcra Kurulu Başkanı

CN¥1.7m

Toplam tazminat

CEO maaş yüzdesi	96.0%
CEO görev süresi	14.3yrs
CEO sahipliği	36.3%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	3.4yrs

Son yönetim güncellemeleri

Recent updates

Yonghe Medical Group Co., Ltd.'s (HKG:2279) Shares Leap 60% Yet They're Still Not Telling The Full Story

Sep 30

Is Yonghe Medical Group (HKG:2279) Using Debt Sensibly?

May 24

It's Down 34% But Yonghe Medical Group Co., Ltd. (HKG:2279) Could Be Riskier Than It Looks

Mar 31

Are Yonghe Medical Group Co., Ltd. (HKG:2279) Investors Paying Above The Intrinsic Value?

Oct 19

The Consensus EPS Estimates For Yonghe Medical Group Co., Ltd. (HKG:2279) Just Fell Dramatically

Sep 08

Is Yonghe Medical Group Co., Ltd. (HKG:2279) Expensive For A Reason? A Look At Its Intrinsic Value

Aug 19

Yonghe Medical Group's (HKG:2279) Soft Earnings Don't Show The Whole Picture

Mar 31

CEO Tazminat Analizi

Yu Zhang'un ücretlendirmesi Yonghe Medical Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥453m
Mar 31 2024	n/a	n/a	-CN¥496m
Dec 31 2023	CN¥2m	CN¥2m	-CN¥538m
Sep 30 2023	n/a	n/a	-CN¥430m
Jun 30 2023	n/a	n/a	-CN¥322m
Mar 31 2023	n/a	n/a	-CN¥203m
Dec 31 2022	CN¥1m	CN¥1m	-CN¥84m
Sep 30 2022	n/a	n/a	CN¥6m
Jun 30 2022	n/a	n/a	CN¥95m
Mar 31 2022	n/a	n/a	CN¥107m
Dec 31 2021	CN¥1m	CN¥1m	CN¥118m
Sep 30 2021	n/a	n/a	CN¥121m
Jun 30 2021	n/a	n/a	CN¥125m
Mar 31 2021	n/a	n/a	CN¥136m
Dec 31 2020	CN¥5m	CN¥1m	CN¥147m
Dec 31 2019	CN¥1m	CN¥900k	CN¥36m
Dec 31 2018	CN¥580k	CN¥455k	CN¥54m

Tazminat ve Piyasa: Yu 'ın toplam tazminatı ($USD 236.75K ) Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 232.96K ).

Tazminat ve Kazançlar: Yu şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Yu Zhang (38 yo)

14.3yrs

Görev süresi

CN¥1,716,000

Tazminat

Mr. Yu Zhang is Chairman of the Board, Executive Director & CEO of Yonghe Medical Group Co., Ltd. He joined the Yonghe Medical Group Co., Ltd. in July 2010.He is Founder of onghe Medical Group Co., Ltd. M...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yu Zhang	Chairman of the Board & CEO	14.3yrs	CN¥1.72m	36.29% HK$ 136.1m
Zhimei Han	Executive Director	7.7yrs	CN¥1.10m	0.036% HK$ 136.0k
Hui Zhang	Senior VP of the Integrated Management Center & Executive Director	3.4yrs	CN¥1.10m	4.83% HK$ 18.1m
Yang Xu	Chief Executive Officer of Innovation Business Unit	1.5yrs	Veri yok	Veri yok
Jian Ren	Chief Growth Officer	2.5yrs	Veri yok	Veri yok
Yang SU	Chief Operating Officer of Yonghe Business Line	1.5yrs	Veri yok	Veri yok
Wai Kam Ng	Joint Company Secretary	less than a year	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

39.5yo

Ortalama Yaş

Deneyimli Yönetim: 2279 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yu Zhang	Chairman of the Board & CEO	4.2yrs	CN¥1.72m	36.29% HK$ 136.1m
Zhimei Han	Executive Director	2.4yrs	CN¥1.10m	0.036% HK$ 136.0k
Hui Zhang	Senior VP of the Integrated Management Center & Executive Director	4.2yrs	CN¥1.10m	4.83% HK$ 18.1m
Peng Kuan Chan	Independent Non-Executive Director	3.4yrs	CN¥181.00k	Veri yok
Jihong Liang	Independent Non-Executive Director	2.4yrs	CN¥180.00k	Veri yok
Jiaqi Geng	Non-Executive Director	4.2yrs	Veri yok	0.13% HK$ 494.0k
Xiaopei Li	Independent Non-Executive Director	3.4yrs	CN¥180.00k	Veri yok

3.4yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2279 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).

Yonghe Medical Group Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Yonghe Medical Group Co., Ltd. Announces Change of Joint Company Secretary

Yonghe Medical Group Co., Ltd., Annual General Meeting, Jun 21, 2024

High number of new and inexperienced directors

Yonghe Medical Group Co., Ltd. Announces Change of Joint Company Secretary, Authorised Representative and Process Agent

Yonghe Medical Group Co., Ltd. Announces Executive Changes

High number of new and inexperienced directors

Recent updates

New major risk - Revenue and earnings growth

Yonghe Medical Group Co., Ltd.'s (HKG:2279) Shares Leap 60% Yet They're Still Not Telling The Full Story

New minor risk - Share price stability

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.44 loss in 1H 2023)

Yonghe Medical Group Co., Ltd. Announces Change of Joint Company Secretary

Yonghe Medical Group Co., Ltd. to Report First Half, 2024 Results on Aug 22, 2024

Consensus EPS estimates fall by 32%

Is Yonghe Medical Group (HKG:2279) Using Debt Sensibly?

Consensus EPS estimates have been downgraded.

It's Down 34% But Yonghe Medical Group Co., Ltd. (HKG:2279) Could Be Riskier Than It Looks

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Yonghe Medical Group Co., Ltd., Annual General Meeting, Jun 21, 2024

Yonghe Medical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Are Yonghe Medical Group Co., Ltd. (HKG:2279) Investors Paying Above The Intrinsic Value?

First half 2023 earnings released: CN¥0.44 loss per share (vs CN¥0.034 profit in 1H 2022)

Yonghe Medical Group Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Price target decreased by 13% to HK$9.88

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

Consensus revenue estimates fall by 17%

The Consensus EPS Estimates For Yonghe Medical Group Co., Ltd. (HKG:2279) Just Fell Dramatically

Yonghe Medical Group Co., Ltd. Announces Change of Joint Company Secretary, Authorised Representative and Process Agent

First half 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.10 in 1H 2021)

Investor sentiment deteriorated over the past week

Is Yonghe Medical Group Co., Ltd. (HKG:2279) Expensive For A Reason? A Look At Its Intrinsic Value

Yonghe Medical Group Co., Ltd. to Report First Half, 2022 Results on Aug 29, 2022

Consensus EPS estimates fall by 13%

Yonghe Medical Group Co., Ltd. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Yonghe Medical Group Co., Ltd. Approves to Declare Final Dividend for the Year Ended December 31, 2021

Yonghe Medical Group Co., Ltd. Announces Executive Changes

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Yonghe Medical Group's (HKG:2279) Soft Earnings Don't Show The Whole Picture

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Yonghe Medical Group Co., Ltd. has completed an IPO in the amount of HKD 1.491899 billion.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş